Top Content

view more
article-block

SolasCure partners with US Army for better wound care technology

SolasCure, a biotechnology company that is dedicated to working towards filling the current market gap in debridement – the removal of necrotic tissue to encourage healing – and healing solutions for chronic wounds has announced a partnership with the US Army’s Institute of Surgical Research (USAISR).

 6 December 2024
article-block

Spinal cord stimulator with AI technology receives CE mark certification

The HFX iq, a personalised spinal cord stimulation (SCS) system developed by Nevro that leverages artificial intelligence technology to manage chronic pain, has received CE mark certification in Europe.

 6 December 2024
article-block

Aravax expands to Oxford Science Park, boosting UK pharmaceutical development

Aravax, a biotechnology company specialising in next-generation immunotherapies, has launched a UK subsidiary at the Oxford Science Park.

 6 December 2024
article-block

Infrareal acquires former Takeda pharma and biotech site in Austria

Infrareal holding has announced that it has entered into a corresponding transfer agreement with Takeda to acquire the 24-hectare site in Orth, Lower Austria – subject to merger control approval from Austrian regulators.

 6 December 2024
article-block

Improving the patient experience: insights from Uganda, the UK and the US

Improving patient experience is increasingly recognised as essential to enhancing healthcare quality, satisfaction and health outcomes across the globe. By understanding the unique challenges and opportunities in different regions, healthcare systems can develop more effective, patient-centred care models.

 6 December 2024
article-block

Precision medicine and the role of pathologists in multidisciplinary bladder cancer care

How can the combined power of multidisciplinary teams and precision medicine be harnessed for people living with bladder cancer?

 5 September 2024

Industry Insights

view more
article-block

Improving the patient experience: insights from Uganda, the UK and the US

Improving patient experience is increasingly recognised as essential to enhancing healthcare quality, satisfaction and health outcomes across the globe. By understanding the unique challenges and opportunities in different regions, healthcare systems can develop more effective, patient-centred care models.

 6 December 2024
article-block

Sustainable drug delivery devices: striking a balance between aspirations and current possibilities

Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable

 17 July 2024
article-block

Exploring disease modification to change the future of epilepsy treatment

Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies

 17 July 2024
article-block

The role of AI in patient support

Rajul Jain from ProPharma considers how AI can be used in patient support, especially considering how it can be used to streamline operations and supplement human expertise

 17 July 2024
article-block

20 years of EGFR in NSCLC: how precision medicine helps navigate lung cancer challenges

Henar Hevia at Johnson & Johnson considers the progress that has been made in lung cancer treatment since the discovery of EGFR, including the evolving treatment paradigm, the role of precision medicine in treatment decision-making and quality of life for patients receiving targeted treatments

 4 June 2024
article-block

Paediatric clinical trials for obesity treatment

Alan Baldridge and Heather Peterson from ICON consider the prevalence of paediatric obesity and assess clinical trials of its treatments

 4 June 2024

Mergers & Acquisitions

view more
article-category

Infrareal acquires former Takeda pharma and biotech site in Austria

Infrareal holding has announced that it has entered into a corresponding transfer agreement with Takeda to acquire the 24-hectare site in Orth, Lower Austria – subject to merger control approval from Austrian regulators.

article-category

Double acquisition by Astoriom helps cement its UK and US presence

Global leader in R&D sample stability and biorepository storage Astoriom has announced the acquisition of both MTS Cryo stores and Cool Repair Scientific UK (both Nottingham, UK).

article-category

Axol Bioscience acquires Phenocell

Earlier this year, Axol Bioscience announced the acquisition of Phenocell SAS with the goal of expanding cell models and services to include dermatology and ophthalmology.

article-category

Stelis, Strides and Steriscience merge to form new CDMO

The CDMO launched earlier this year at the CPHI conference in Milan, Italy.

article-category

University of Edinburgh spinout Kynos Therapeutics acquired by Dr. Falk Pharma

Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase (kmo) inhibitors – has been acquired by Dr. Falk Pharma.

article-category

EyeBio to be acquired by Merck for an upfront $1.3bn

Merck and EyeBiotech Limited, have announced that the two companies have entered into a definitive agreement under which Merck, through one of its subsidiaries, will acquire EyeBio.

article-category

Chemaxon to be acquired by Certara for drug discovery

Certara and Chemaxon have announced that they have signed a definitive agreement under which Certara will acquire Chemaxon.

article-category

Icon Group acquires Pharmaxo as part of strategic partnership

Pharmaxo has announced that it is joining Icon Group as part of a strategic partnership intended to establish a global compounding operator as well as to allow icon to enter the UK market.

article-category

Human Immunology Biosciences to be aquired by Biogen for $1.15bn

Biogen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive agreement for Biogen to acquire HI-Bio for $1.15bn upfront, alongside up to $650m in potential milestone payments.

article-category

Mirus Bio to be acquired by Merck for $600m

Merck has announced that it has signed a definitive agreement to acquire Mirus Bio for $600m.

article-category

Landos Biopharma to be acquired by AbbVie for approximately $137.5m

AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under which AbbVie will acquire Landos for an approximate $137.5m ‒ or $20.42 per share ‒ adding to its portfolio in inflammatory and autoimmune diseases.

article-category

Alpine Immune Sciences to be acquired by Vertex for $4.9bn

Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share, totalling an approximate $4.9bn.

article-category

Johnson & Johnson announces acquisition of Shockwave Medical for $13.1bn

Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J will acquire all outstanding shares of Shockwave Medical for $335 per share, or a total value of $13.1bn.

article-category

Amneal and Zambon Biotech to collaborate for Parkinson’s treatment

Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the EU, UK and Switzerland.

article-category

Fusion Pharmaceuticals to be acquired by AstraZeneca for approximately $2bn

AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn.

article-category

Harpoon Therapeutics acquired by Merck for $650m

Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon Therapeutics, meaning it is now a wholly owned subsidiary of Merck.

Approvals

view more
article-category

Johnson & Johnson receives MHRA approval for BALVERSA

BALVERSA (erdafitinib) has been granted marketing approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of the most common type of bladder cancer, metastatic or unresectable urothelial carcinoma.

article-category

Theramex receives recommendation for YSELTY in Scotland

Theramex, a dedicated women’s health company, has announced that the Scottish Medicines Consortium (SMC) has recommended YSELTY (linzagolix) for the treatment of moderate or severe symptoms of uterine fibroids (UFs) in adult women of reproductive age.

article-category

MHRA greenlights adapted nuvaxovid JN.1 COVID-19 vaccine for ages 12 and up

Approval of an updated version of the Nuvaxovid COVID-19 vaccine, developed by Novavax, has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA), to target the omicron JN.1 COVID-19 subvariant.

article-category

J&J seeks approval for first drug to treat high-risk smouldering myeloma

Earlier in November, Johnson & Johnson Innovative Medicine have applied to the US Food and Drug Agency (FDA) and the European Medicines Agency (EMA) for the approval of a new indication for DARZALEX FASPRO (daratumumab and hyluronidase-fihj).

article-category

NICE gives positive recommendation for Santen’s Roclanda

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Santen’s Roclanda (netarsudil 0.02% and latanoprost 0.005%) as an option for patients suffering from primary open-angle glaucoma (poag) or ocular hypertension.

article-category

CHMP adopts positive opinion for new breast cancer drug, Kisquali, from Novartis

Last month, the Committee for Medicinal Products for Human Use (CHMP), which is part of the European Medicines Agency (EMA) announced that it has adopted a positive opinion for Novartis’ Kisquali (ribociclib) as an adjuvant in the treatment of adults with hormone receptor-positive/human epidermal growth factor 2negative (hr+/her2-) early breast cancer (ebc).

article-category

Eplontersen recommended for EU approval by CHMP for hereditary transthyretin-mediated amyloidosis

Wainzua (Eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the EU by the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP). The drug will be used as a treatment for hereditary transthyretin-mediated amyloidosis in adult patients who have stage 1 or 2 polyneuropathy (commonly referred to as hattr-pn or attrv-pn).

article-category

CytexOrtho receives FDA greenlight for clinical trials into joint repair technology

Clinical stage medical device company CytexOrtho has announced approval from the US Food and Drug Administration (FDA) for its planned phase 1 clinical trial into orthopaedic joint preservation and repair.

article-category

Headlands Research opens new clinical trials site in El Paso, Texas, to serve Hispanic population

Headlands Research, a multinational network of clinical research sites, has launched a new clinical trials site in El Paso, Texas, US.

article-category

Biologic medicine Dupixent approved by FDA for COPD patients in the US

The US Food and Drug Administration has approved Sanofi’s Dupixent as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.

article-category

Tiziana Life Sciences awarded $4m grant by NIH to study anti-CD3 in Alzheimer’s disease

Tiziana Life Sciences, a biotechnology company developing immunomodulation therapies, announced that the National Institutes of Health (NIH),'s National Institute on Aging has awarded a $4m grant to Dr Howard Weiner as principal investigator at Brigham and Women’s Hospital to be the key research site to study nasal anti-cd3 for the treatment of alzheimer’s disease (ad).

article-category

European Commission approves Astellas Pharma’s GEJ adenocarcinoma treatment

The European Commission (EC) has approved Astellas Pharma’s vyloy (zolbetuximab) in combination with fluoropyrimidine and platinum-containing chemotherapy as a treatment for adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are claudin (CLDN) 18.2 positive.

article-category

Ministry of Health, Labour and Welfare of Japan approves new drug for early Alzheimer’s disease

The Ministry of Health, Labour and Welfare Japan has approved treatment for Eli Lilly’s KINSULA, indicated for adult patients with early symptomatic Alzheimer’s disease (AD). This also includes patients with mild dementia stage AD, and mild cognitive impairment.

article-category

New collaboration agreement announced between EMIH association and the MTIG

The European Microbiome Innovation for Health (EMIH) association and the Microbiome Therapeutics Innovation Group (MTIG) have announced a new collaborative agreement. The agreement seeks to advance microbiome drug development by improving collaboration between the two microbiome focused coalitions.

article-category

FDA approves first drug in 50 years for treatment of schizophrenia in adults

Earlier this September, the US Food and Drug Administration (FDA) granted approval for PureTech Health’s Karxt for the treatment of schizophrenia in adults, triggering royalty payments of $29m to PureTech. It will be the first approved mechanism by the FDAfor schizophrenia in over 50 years.

article-category

Third application for Orion’s prostate cancer drug submitted by partner Bayer

Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, darolutamide, in the US.

General News

view more
article-category

SolasCure partners with US Army for better wound care technology

SolasCure, a biotechnology company that is dedicated to working towards filling the current market gap in debridement – the removal of necrotic tissue to encourage healing – and healing solutions for chronic wounds has announced a partnership with the US Army’s Institute of Surgical Research (USAISR).

article-category

Spinal cord stimulator with AI technology receives CE mark certification

The HFX iq, a personalised spinal cord stimulation (SCS) system developed by Nevro that leverages artificial intelligence technology to manage chronic pain, has received CE mark certification in Europe.

article-category

Antibacterial peptides instrumental in efficiency against resistant bacteria

Earlier in November, the Chalmers University of Technology in Sweden published the results of a study demonstrating that resistant bacteria, when paired with material equipped with antibacterial peptides, can regain susceptibility to antibiotics.

article-category

Cytomos raises £5m for scale-up process

Biotech company Cytomos has announced this month that it has raised £5m to scale up the production of its unique cell analysis technology.

article-category

Revolutionary Alzheimer’s diagnostic blood test launches in the UK

Advance Tests, committed to enhancing diagnostic accessibility and advancing early disease detection, announced the exclusive UK launch of LucentAD complete.

article-category

Survey from Roche finds worryingly low understandings about HPV and cervical cancer

Questioning almost 9,000 participants across 12 countries in Latin America and Europe, the research revealed significant knowledge gaps surrounding human papillomavirus (HPV) and highlighted several significant barriers preventing women from screening for it.

article-category

Best-in-class AI model from Bioptimus integrated into Proscia’s leading software platform

French start-up Bioptimus has announced that its H-optimus-o biology reference artificial intelligence (AI) foundation model has been wholly integrated into Proscia’s Concentriq embeddings software platform, with the aim of enabling quicker and more efficient breakthroughs in ai development for therapeutic research.

article-category

Almirall’s Immunoskin event returns for a third year, discussing medical dermatology advances

Hosted again in Barcelona, Spain, the Immunoskin conference ran from 26-27 October and brought together leading experts in dermatological conditions and treatments.

article-category

EcoVadis Platinum medal given to Liveo Research’s Singapore pharma packaging site

Liveo Research, a leading primary packaging manufacturer, has had the EcoVadis rating of its Singapore site increased from gold to platinum. This means that the pharma packaging site is now rated in the top 1% of the 100,000 companies evaluated by ecovadis in its annual global surveys.

article-category

HUTCHMED set to receive $20m in funding from Takeda for colorectal cancer drug sales

In late October, HUTCHMED’s partner Takeda will pay a milestone payment of $20m as the result of over $200m worth of sales for Fruzaqla (fruquintinib), which treats metastatic colorectal cancer (CRC).

article-category

Exhibitor numbers for CPHI India grow for third year in a row, with 50,000 attendees expected

Running from 26-28 November 2024, the largest pharma event in India is expected to have a record attendance of delegates from more than 150 countries, with over 2,000 exhibitors also expected.

article-category

PacBio announces update to sequencing system to bring down cost of genome sample to below $500

Announced by PacBio, known for developing sequencing solutions, SPRQ has the potential to significantly reduce the cost of sequencing genomes.

article-category

HIV vaccine candidate successfully optimised for industrial production

Sumagen Canada Inc, a biotech company based in both South Korea and Canada, has partnered with CDMO Naobios to industrialise Sumagen’s human immunodeficiency virus (HIV)-1 vaccine candidate (sav0001) at bench scale.

article-category

Bayer and Liveo Research pair to launch new sustainable blister packaging

The partnership between the two companies has resulted in the launching of a first-of-its-kind blister packaging, utilising polyethylene terephthalate (PET) instead of the more traditional poly vinyl chloride (PVC).

article-category

NRG Therapeutics secures funding for development of treatment for neurodegenerative disease

NRG Therapeutics has announced that its NRG5051 inhibitor has secured a $5m grant from the Michael J. Fox foundation for Parkinson’s research (MJFF).

article-category

CluePoints launches Medical & Safety Review (MSR) software

Risk-based quality management (RBQM) and data quality oversight software company Cluepoints launches its latest application, the medical & safety review (MSR), to simplify and streamline the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning, query management and full transparency over the data history.

How to Install

Appointments

view more
article-category

Michael Garrett appointed as new chief executive officer at ExeVir Bio

Exevir Bio, a biotech company focused on developing heavy chain-only antibodies to target highly conserved epitopes for broad-spectrum protection against infectious diseases, has announced the appointment of Michael Garrett as its new CEO.

article-category

Double hiring strengthens Biosynth upper management

Biosynth – known for supplying the life sciences industry with critical raw materials and services – has announced that Matt Gunnison has been appointed as its new CEO and Kieran Murphy has been appointed as chairman.

article-category

Veronica Gambillara Fonck nominated as chair of MinervaX’s board of directors

Following the stepping down of the previous chair, Gerd Zettlmeissl, MinervaX has appointed Veronica Gambillara Fonck to lead the board of directors.

article-category

Darrin Schellin appointed new CEO at Pharma Tech Industries

Pharma Tech Industries, a pharmaceutical manufacturing and packaging solutions contractor for wellness products and medical devices, has announced the appointment of its new chief executive officer, Darrin T Schellin.

article-category

CluePoints appoint Richard Young as chief strategy officer

Cluepoints, a data quality oversight and and risk-based quality management software provider, has announced the appointment of Richard Young as its chief strategy officer.

article-category

Dr Souad Kechairi appointed chief medical officer at PLL Therapeutics

Dr Souad Kechairi has been appointed chief medical officer at PLL Therapeutics, a biopharmaceutical company specialising in polypeptides.

article-category

Shawn Cross appointed as chief financial officer for Pacira Biosciences

Pacira biosciences, specialist in non-opioid pain therapies, has appointed Shawn Cross as its chief financial officer. In this role, Mr Cross will take over all responsibility for the company’s financial operations.

article-category

Prilenia appoints new staff to advance company’s development plans

Prilenia, a clinical stage biotech focusing on neurodegenerative and neurodevelopmental disorders, has announced the appointment of two new senior staff members ‒ Rob Lauzen as chief financial officer (CFO) and Jason Marks as chief legal officer (CLO).

article-category

Steriline’s founder ‘passes torch’ to children with CEO and CSO appointments

Aseptic packaging company Steriline’s founder Gerardo Fumagalli has ‘passed the torch’ to his children Illaria Fumagalli and Federico Fumagalli, who have been appointed to chief executive officer and chief sales officer, respectively. Gerardo will continue on as chairman of the board of directors.

article-category

Eli Lilly expands with two senior hires in Public Affairs and Communications team

Pharmaceutical company Eli Lilly has announced the appointment of two senior positions in its public affairs and communications team.

article-category

Dr Anada Gubbi appointed by SFA Therapeutics as director of Biostatistics

SFA Therapeutics, a clinical-stage biopharmaceutical company, has announced that it has appointed Dr Anada Gubbi as director of biostatistics. Dr Gubbi will be responsible for assisting SFA Therapeutics in effectively developing drug candidates for the treatment of inflammatory diseases.

article-category

Curve Therapeutics bolsters its leadership team with appointment of Simon Jones

With his 20 years of expertise and proven track record in biotech and pharmaceutical industries, Curve Therapeutics appoints Simon Jones as chief financial officer and chief operating officer.

article-category

Adam Rosenberg replaces Dr Carlo Incerti as new chair of the board at VectorY Therapeutics

Vectory Therapeutics has announced the appointment of Adam Rosenberg as chair of the board, replacin Dr Carlo Incerti.

article-category

Dr Jonathan Appleby appointed by Mogrify as chief scientific officer

Mogrify has announced the appointment of Dr Jonathan Appleby as chief scientific officer.

article-category

Professor yih-shing duh appointed as chief scientific advisor by H.E.L. Group

Professor Yih-Shing Duh appointed as chief scientific advisor by H.E.L. Group

article-category

Enhanc3D Genomics appoints Hazel Jones as CEO

Enhanc3D Genomics has announced the appointment of Hazel Jones as chief executive officer (CEO), following a successful six-month term as interim CEO and COO.